ISSN 1673-3770 CN 37-1437/R
山东大学耳鼻喉眼学报 ›› 2014, Vol. 28 ›› Issue (4): 77-80.doi: 10.6040/j.issn.1673-3770.0.2013.318
盛宏申1, 何跃1, 黄德亮2, 韩东一2, 杨仕明2, 戴朴2, 武文明2
SHENG Hong-shen1, HE Yue1, HUANG De-liang2, HAN Dong-yi2, YANG Shi-ming2, DAI Pu2, WU Wen-ming2
摘要： 目的 研究颈静脉球瘤（GJT）中胰岛素样生长因子-1（IGF-1）、细胞外信号调节激酶1/2（ERK1/2）的表达及意义。方法 应用免疫组织化学方法，检测33例GJT及9例正常肾上腺髓质中IGF-1、ERK1/2的表达情况。结果 33例GJT中IGF-1表达阳性26例。阳性细胞主要为主细胞，染色部位主要为细胞浆，部分细胞核亦呈阳性染色。9例肾上腺髓质中IGF-1阳性表达5例，染色部位为细胞浆，染色强度明显低于肿瘤组织。33例GJT中ERK1/2阳性表达分别为24例、25例，阳性物质均位于细胞浆。9例肾上腺髓质中ERK1/2阳性表达分别为4例、5例，其表达强度明显低于肿瘤组织。IGF-1表达与ERK1/2表达之间呈正相关，相关系数分别为0.553、0.601（P<0.05）。结论 IGF-1可能以旁分泌或自分泌的方式并通过ERK1/2信号转导途径在GJT的形成及发展中发挥作用。
中图分类号:
| [1] Gallagher E J, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer[J]. Trends Endocrinol Metab, 2010, 21(10):610-618. [2] Li S L, Goko H, Xu Z D, et al. Expression of insulin-like growth factor (IGF)-Ⅱ in human prostate, breast, bladder, and paraganglioma tumors[J]. Cell Tissue Res, 1998, 291(3):469-479. [3] Kontogeorgos G, Scheithauer B W, Kovacs K, et al. Growth factors and cytokines in paragangliomas and pheochromocytomas, with special reference to sustentacular cells[J]. Endocr Pathol, 2002, 13(3):197-206. [4] 于萍, 步宏, 王华, 等. 免疫组化结果的图像分析与人工计数方法的对比研究[J]. 生物医学工程学杂志, 2003, 20(2):288-290. [5] Pavelić J, Matijević T, Knezević J. Biological & physiological aspects of action of insulin-like growth factor peptide family[J]. Indian J Med Res, 2007, 125(4):511-522. [6] Rosenzweig S A, Atreya H S. Defining the pathway to insulin-like growth factor system targeting in cancer[J]. Biochem Pharmacol, 2010, 80(8):1115-1124. [7] McCubrey J A, Steelman L S, Chappell W H, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance[J]. Oncotarget, 2012, 3(10):1068-1111. [8] Wei F, Yan J, Tang D. Extracellular signal-regulated kinases modulate DNA damage response-a contributing factor to using MEK inhibitors in cancer therapy[J]. Curr Med Chem, 2011, 18(35):5476-5482. [9] Roberts P J, Der C J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer[J]. Oncogene, 2007, 26(22):3291-3310. [10] 赵萌, 刘月平, 刘世正, 等.食管鳞癌中ERK及其活化形式蛋白的表达及意义[J]. 临床与实验病理学杂志, 2011, 27(11):1173-1176. [11] 谷艳娇, 包翠芬, 魏嘉, 等.ERK1/2和p-ERK1/2在肺癌组织中的表达及意义[J]. 中国组织化学与细胞化学, 2009, 18(3):328-331. [12] Ebisuya M, Kondoh K, Nishida E. The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity[J]. J Cell Sci, 2005, 118(14):2997-3002. |
| [1] | 苗北平1,张蕊石2,郭志红3,徐化剑4,孙艳花5,雷大鹏6,卢永田1. 颈静脉球瘤诊断与治疗(附8例报告)[J]. 山东大学耳鼻喉眼学报, 2013, 27(4): 47-50. |
|
||